Phil Secures $60 Million Growth Capital Facility from K2 HealthVentures to Accelerate AI Integration

portfolio company news
Written By Megan Prock McGrath

Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.

Megan Prock McGrath
Previous

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Next

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway